177 results
8-K
EX-99.1
VXRT
Vaxart Inc
13 May 24
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
4:03pm
to decreases in personnel related costs and clinical trial expenses related to Vaxart’s norovirus vaccine candidate, partially offset by increased … in personnel stock-based expense and recruiting costs, partially offset by decreases in directors' and officers' insurance and legal fees.
Conference
8-K
EX-99.1
VXRT
Vaxart Inc
14 Mar 24
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
4:05pm
costs, personnel related costs and clinical trial expenses related to Vaxart’s COVID-19 vaccine candidates, partially offset by increased facilities … is primarily due to decreases in legal and professional fees, litigation settlement costs and directors' and officers' insurance, partially offset
8-K
EX-99.1
gjtdkvx43
2 Nov 23
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
wyrmkhg8m9a
3 Aug 23
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
4:20pm
8-K
EX-99.1
pr4q6ybd7ouu
4 Nov 21
Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results
4:06pm
8-K
EX-10.1
crg9l o1vx1nvd6
21 Sep 21
Entry into a Material Definitive Agreement
4:18pm
8-K
EX-99.1
lwk6gq 67bqy2
5 Aug 21
Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results
4:08pm
8-K
0adga pkivh
2 Aug 21
Results of Operations and Financial Condition
4:11pm